These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

169 related items for PubMed ID: 10949981

  • 41.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 42. Effectiveness of short-course therapy (5 days) with grepafloxacin in the treatment of acute bacterial exacerbations of chronic bronchitis.
    DeAbate CA, Bettis R, Munk ZM, Fleming H, Munn NJ, Riffer E, Bagby B, Giguere G, Collins JJ.
    Clin Ther; 1999 Jan; 21(1):172-88. PubMed ID: 10090434
    [Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47. Susceptibilities of Haemophilus influenzae, Streptococcus pneumoniae, including serotype 19A, and Moraxella catarrhalis paediatric isolates from 2005 to 2007 to commonly used antibiotics.
    Harrison CJ, Woods C, Stout G, Martin B, Selvarangan R.
    J Antimicrob Chemother; 2009 Mar; 63(3):511-9. PubMed ID: 19174454
    [Abstract] [Full Text] [Related]

  • 48. Telithromycin is as effective as amoxicillin/clavulanate in acute exacerbations of chronic bronchitis.
    Aubier M, Aldons PM, Leak A, McKeith DD, Leroy B, Rangaraju M, Bienfait-Beuzon C.
    Respir Med; 2002 Nov; 96(11):862-71. PubMed ID: 12418583
    [Abstract] [Full Text] [Related]

  • 49. Efficacy and safety of 3-day azithromycin versus 5-day moxifloxacin for the treatment of acute bacterial exacerbations of chronic bronchitis.
    Zervos M, Martinez FJ, Amsden GW, Rothermel CD, Treadway G.
    Int J Antimicrob Agents; 2007 Jan; 29(1):56-61. PubMed ID: 17189096
    [Abstract] [Full Text] [Related]

  • 50. Comparative in vitro activity of a pharmacokinetically enhanced oral formulation of amoxicillin/clavulanic acid (2000/125 mg twice daily) against 9172 respiratory isolates collected worldwide in 2000.
    Koeth LM, Jacobs MR, Good CE, Bajaksouzian S, Windau A, Jakielaszek C, Saunders KA.
    Int J Infect Dis; 2004 Nov; 8(6):362-73. PubMed ID: 15494258
    [Abstract] [Full Text] [Related]

  • 51. Effects of amoxicillin/clavulanate or azithromycin on nasopharyngeal carriage of Streptococcus pneumoniae and Haemophilus influenzae in children with acute otitis media.
    Ghaffar F, Muniz LS, Katz K, Reynolds J, Smith JL, Davis P, Friedland IR, McCracken GH.
    Clin Infect Dis; 2000 Oct; 31(4):875-80. PubMed ID: 11049764
    [Abstract] [Full Text] [Related]

  • 52. Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study.
    File TM, Mandell LA, Tillotson G, Kostov K, Georgiev O.
    J Antimicrob Chemother; 2007 Jul; 60(1):112-20. PubMed ID: 17537866
    [Abstract] [Full Text] [Related]

  • 53. In vitro activity of gemifloxacin against recent clinical isolates of bacteria in Korea.
    Yong DE, Cheong HJ, Kim YS, Park YJ, Kim WJ, Woo JH, Lee KW, Kang MW, Choo YS.
    J Korean Med Sci; 2002 Dec; 17(6):737-42. PubMed ID: 12482994
    [Abstract] [Full Text] [Related]

  • 54. Trovafloxacin versus high-dose amoxicillin (1 g three times daily) in the treatment of community-acquired bacterial pneumonia.
    Trémolières F, de Kock F, Pluck N, Daniel R.
    Eur J Clin Microbiol Infect Dis; 1998 Jun; 17(6):447-53. PubMed ID: 9758291
    [Abstract] [Full Text] [Related]

  • 55. Antimicrobial selection for community-acquired lower respiratory tract infections in the 21st century: a review of gemifloxacin.
    Appelbaum PC, Gillespie SH, Burley CJ, Tillotson GS.
    Int J Antimicrob Agents; 2004 Jun; 23(6):533-46. PubMed ID: 15194123
    [Abstract] [Full Text] [Related]

  • 56. Pharmacokinetically enhanced amoxicillin/clavulanate (2,000/125 mg) in acute bacterial rhinosinusitis caused by Streptococcus pneumoniae, including penicillin-resistant strains.
    Anon JB, Ferguson B, Twynholm M, Wynne B, Berkowitz E, Poole MD.
    Ear Nose Throat J; 2006 Aug; 85(8):500, 502, 504 passim. PubMed ID: 16999056
    [Abstract] [Full Text] [Related]

  • 57. Impact of gemifloxacin on the normal human intestinal microflora.
    Barker PJ, Sheehan R, Teillol-Foo M, Palmgren AC, Nord CE.
    J Chemother; 2001 Feb; 13(1):47-51. PubMed ID: 11233800
    [Abstract] [Full Text] [Related]

  • 58. Efficacy and safety of a 10-day course of 400 or 600 milligrams of grepafloxacin once daily for treatment of acute bacterial exacerbations of chronic bronchitis: comparison with a 10-day course of 500 milligrams of ciprofloxacin twice daily.
    Chodosh S, Lakshminarayan S, Swarz H, Breisch S.
    Antimicrob Agents Chemother; 1998 Jan; 42(1):114-20. PubMed ID: 9449270
    [Abstract] [Full Text] [Related]

  • 59. Comparative evaluation of the clinical and microbiological efficacy of co-amoxiclav vs cefixime or ciprofloxacin in bacterial exacerbation of chronic bronchitis.
    Cazzola M, Vinciguerra A, Beghi GF, Paizis G, Giura R, Madonini V, Fiorentini F, Consigli GF, Tonna M, Casalini A.
    J Chemother; 1995 Oct; 7(5):432-41. PubMed ID: 8596127
    [Abstract] [Full Text] [Related]

  • 60. Lomefloxacin versus amoxicillin in the treatment of acute exacerbations of chronic bronchitis: an Italian multicenter study.
    Grassi C, Albera C, Pozzi E.
    Am J Med; 1992 Apr 06; 92(4A):103S-107S. PubMed ID: 1316058
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.